Suggested remit: To appraise the clinical and cost effectiveness of somapacitan within its marketing authorisation for treating children with growth hormone deficiency.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6178

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Newcastle NIHR TAR Team, Newcastle University


Companies sponsors Novo Nordisk (somapacitan)
Others Department of Health and Social Care
  NHS England
Patient carer groups Child Growth Foundation
Professional groups Royal College of Physicians
Associated public health groups None
Comparator companies Ipsen (somatropin) (confidentiality agreement not signed, not participating)
  Lilly (somatropin) (confidentiality agreement not signed, not participating)
  Merck Serono (somatropin) (confidentiality agreement not signed, not participating)
  Novo Nordisk (somatropin) (confidentiality agreement not signed, not participating)
  Pfizer (somatrogon, somatropin) (confidentiality agreement not signed, not participating)
  Sandoz (somatropin) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology
  British National Formulary
  Department of Health, Social Services
  and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products
  Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services
Relevant research groups None


Key events during the development of the guidance:

Date Update
25 May 2023 Invitation to participate
20 January 2023 - 17 February 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6178
20 January 2023 In progress. Scoping commencing
28 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual